KPV Safety Profile KPV demonstrates a favorable safety profile in all preclinical studies reviewed, with no acute toxicity at therapeutic doses
These findings establish the mechanistic basis for the compound and provide proof of concept for its metabolic effects
L CARNITINA LQUIDA PARA QUE SERVE
is a Wallenberg Scholar and a Distinguished Professor at the Swedish Research Council supported by grants from the Swedish Research Council (grant numbers 2023-00356, 2022-01018 and 2019-02397), the European Unions Horizon Europe research and innovation programme under grant agreement number 101053962, Swedish State Support for Clinical Research (grant number ALFGBG-71320), the Alzheimer Drug Discovery Foundation (ADDF), USA (grant numbers 201809-2016862), the AD Strategic Fund and the Alzheimers Association (grant numbers ADSF-21-831376-C, ADSF-21-831381-C, ADSF-21-831377-C and ADSF-24-1284328-C), the European Partnership on Metrology, co-financed from the European Unions Horizon Europe research and innovation programme and by the participating States (NEuroBioStand, grant number 22HLT07), the Bluefield Project, Cure Alzheimers Fund, the Olav Thon Foundation, the Erling-Persson Family Foundation, Familjen Rnstrms Stiftelse, Stiftelsen fr Gamla Tjnarinnor, Hjrnfonden, Sweden (grant number FO2022-0270), the European Unions Horizon 2020 research and innovation programme under the Marie Skodowska-Curie grant agreement number 860197 (MIRIADE), the European Union Joint ProgrammeNeurodegenerative Disease Research (grant number JPND2021-00694), the National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre, the UK Dementia Research Institute at UCL (grant number UKDRI-1003) and an anonymous donor
Reducing it creates conditions more favorable for regeneration
